The opinions or assertions presented herein are the private views of the authors and are not to be construed as conveying either an official endorsement or criticism by the US Department of Health and Human Services, the Public Health Service, or the Food and Drug Administration.
Tumor necrosis factor α blockers and malignancy in children: Forty-eight cases reported to the food and drug administration†
Article first published online: 13 APR 2010
Copyright © 2010 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 62, Issue 8, pages 2517–2524, August 2010
How to Cite
Diak, P., Siegel, J., La Grenade, L., Choi, L., Lemery, S. and McMahon, A. (2010), Tumor necrosis factor α blockers and malignancy in children: Forty-eight cases reported to the food and drug administration. Arthritis & Rheumatism, 62: 2517–2524. doi: 10.1002/art.27511
- Issue published online: 3 AUG 2010
- Article first published online: 13 APR 2010
- Manuscript Accepted: 6 APR 2010
- Manuscript Received: 17 SEP 2009
Malignancies reported in children using tumor necrosis factor α (TNFα) blockers have raised concerns of a potential increased risk. This study was undertaken to investigate postmarketing reports of malignancy in children treated with TNF blockers.
The FDA's Adverse Event Reporting System was searched to identify malignancies associated with the use of infliximab, etanercept, and adalimumab in children in whom therapy was initiated between the ages of 0 and 18 years. The reporting rates for infliximab and etanercept were compared with the background rate of malignancy in the general pediatric population.
Forty-eight reports of malignancy in children were identified: 31 following infliximab use, 15 following etanercept use, and 2 following adalimumab use. Half of the malignancies reported were lymphomas and included both Hodgkin's and non-Hodgkin's lymphoma. The remaining reported cases involved a variety of different malignancies including leukemia, melanoma, and solid organ cancers. The majority of the reported cases (88%) involved the concomitant use of other immunosuppressants. Reporting rates for malignancy showed that infliximab had a consistently higher reporting rate when compared with background rates in the general pediatric population for lymphomas and all malignancies. The reporting rates for etanercept were elevated above background for lymphomas and were on par with background for all malignancies.
There is evidence that treatment with TNF blockers in children may increase the risk of malignancy. However, the cases were confounded by the potential risk of malignancy associated with underlying illnesses and the use of concomitant immunosuppressants; therefore, a clear causal relationship could not be established.